Statewide legal status
Georgia continues to treat ordinary psilocybin as a Schedule I controlled substance. Personal possession is not authorized.

GA legal and access quick reference
Reviewed July 22, 2026A concise, source-dated explanation of statewide law, regulated access, and the difference between state and local policy.
Laws and implementation can change quickly. This page is educational information, not legal advice.
Georgia continues to treat ordinary psilocybin as a Schedule I controlled substance. Personal possession is not authorized.
Act 634 regulates clinics offering FDA-approved psychedelic-assisted treatments. It requires board rules by December 31, 2026 and clinic licensing beginning July 1, 2027, but it does not permit unapproved psilocybin.
Act 476 creates a conditional state-law pathway for a crystalline-polymorph psilocybin drug only after FDA approval and required federal scheduling changes. Those conditions do not create present consumer access, retail sales, or personal-use legality.
For Athens, Atlanta, Augusta and Savannah, this Georgia page is the appropriate quick-reference starting point because no separate municipal action was retained as a distinct local-policy guide. Local rules can change, so verify current official records.
The statewide explanation above covers Athens, Atlanta, Augusta and Savannah. A separate page appears below only where a documented municipal action adds material local context.
This review uses Georgia’s official 2026 enactment summary and enacted bill records. The clinic law and conditional medication pathway are stated separately because neither creates present general psilocybin access.
Georgia continues to treat ordinary psilocybin as a Schedule I controlled substance. Personal possession is not authorized. Act 634 regulates clinics offering FDA-approved psychedelic-assisted treatments. It requires board rules by December 31, 2026 and clinic licensing beginning July 1, 2027, but it does not permit unapproved psilocybin.
Act 634 regulates clinics offering FDA-approved psychedelic-assisted treatments. It requires board rules by December 31, 2026 and clinic licensing beginning July 1, 2027, but it does not permit unapproved psilocybin.
No. Local enforcement choices do not repeal state law, legalize commercial sales, or create a statewide access program.
The product-site link provides product-format and business-policy information. It does not change the law described on this page or establish legal access in any jurisdiction.